4//SEC Filing
Hansen Graydon C. 4
Accession 0001209191-21-032100
CIK 0000718937other
Filed
May 11, 8:00 PM ET
Accepted
May 12, 5:03 PM ET
Size
26.7 KB
Accession
0001209191-21-032100
Insider Transaction Report
Form 4
Hansen Graydon C.
Sr. VP, Global Operations
Transactions
- Exercise/Conversion
Common Stock
2021-05-11$27.53/sh+10,025$275,988→ 25,453 total - Sale
Common Stock
2021-05-12$110.74/sh−5,531$612,503→ 8,847 total - Exercise/Conversion
Common Stock
2021-05-12$29.80/sh+375$11,175→ 9,222 total - Exercise/Conversion
Common Stock Options
2021-05-11−10,025→ 17,737 totalExercise: $27.53From: 2021-03-20Exp: 2030-03-19→ Common Stock (10,025 underlying) - Exercise/Conversion
Common Stock Options
2021-05-12−348→ 0 totalExercise: $16.15From: 2019-03-15Exp: 2028-03-14→ Common Stock (348 underlying) - Exercise/Conversion
Common Stock
2021-05-12$16.15/sh+348$5,620→ 9,801 total - Exercise/Conversion
Common Stock Options
2021-05-11−1,050→ 7,272 totalExercise: $35.98From: 2020-03-14Exp: 2029-03-13→ Common Stock (1,050 underlying) - Exercise/Conversion
Common Stock Options
2021-05-12−375→ 375 totalExercise: $29.80From: 2019-06-14Exp: 2028-06-13→ Common Stock (375 underlying) - Exercise/Conversion
Common Stock
2021-05-11$35.98/sh+1,050$37,779→ 15,428 total - Sale
Common Stock
2021-05-11$111.61/sh−11,075$1,236,081→ 14,378 total - Exercise/Conversion
Common Stock
2021-05-12$35.98/sh+231$8,311→ 9,453 total - Exercise/Conversion
Common Stock Options
2021-05-12−231→ 7,041 totalExercise: $35.98From: 2020-03-14Exp: 2029-03-13→ Common Stock (231 underlying)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.08 to $113.18, inclusive.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $112.29, inclusive.
- [F3]The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022.
- [F4]The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.
- [F5]The options granted become exercisable as follows: 1/3 on 6/14/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 6/14/2021.
- [F6]The options granted become exercisable as follows: 1/3 on 3/15/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/15/2021.
Documents
Issuer
STAAR SURGICAL CO
CIK 0000718937
Entity typeother
Related Parties
1- filerCIK 0001781933
Filing Metadata
- Form type
- 4
- Filed
- May 11, 8:00 PM ET
- Accepted
- May 12, 5:03 PM ET
- Size
- 26.7 KB